Months ahead of the target action date, the FDA recently approved the pan-RAS inhibitor daraxonrasib (Rasonque) for patients ...
During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...
Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...
Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia. Immune ...
The FDA has granted fast track designation (FTD) to ERAS-0015, an oral pan-RAS molecular glue, clearing an expedited ...
The assays are now approved to assess HER2 status in gastric, gastroesophageal junction, and esophageal adenocarcinoma.
In the GESTALT feasibility and safety trial, GammaTile reduced rapid early progression to 6% vs a historical 50% to 80%, with ...
Oncology leaders weigh how to scale trustworthy AI platforms, align governance, and integrate care-research workflows for ...
The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 1.
Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...
Celcuity seeks FDA expansion for gedatolisib combos in PIK3CA-mutant HR+/HER2- metastatic breast cancer, after VIKTORIA-1 ...
The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results